ALUR

Allurion Technologies Inc. (ALUR) | Rumor.io

Allurion Technologies

ALUR

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio32.9

Market capitalization4.7M

Earnings per share-3.96

Dividend yield (TTM)—

Revenue (annual)15.2M

Net income (annual)-28.8M

Social

What share of all stock conversation is about ALUR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 3

Allurion Technologies Inc. (ALUR) plans to appeal NYSE delisting notice and execute a plan to regain compliance.
The company expects to continue trading on the NYSE despite the delisting proceedings initiated due to listing standard breaches.
Allurion Technologies cites FDA approval in 2026 and remediation steps as reasons for its plan to regain NYSE compliance.

Generated by AI

Sentiment

Of the messages about ALUR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	93.73% +14.44
Bearish	—	—	0%	6.27% -14.44

Bullish· Feb 24

$ALUR has been upgraded to Buy from Neutral by Chardan Capital with a price target of $3, citing FDA approval for its gastric balloon system and increased options for management.
The company has obtained FDA approval for its gastric balloon system, featuring the Allurion Smart Capsule, which significantly increases options available to management to support execution of its business plan.
$ALUR is expected to reach $200 million in revenue within 2 years, with a possible buy opportunity at $1.5-$2 billion range if the company delivers significantly good results.

Bearish· Feb 23

Allurion Technologies Inc. (ALUR) is likely to dilute to a price below $1 due to an 80% dilution risk.
The company has a negative cash position, with only 0.7 months of cash remaining based on a quarterly cash burn of -$7.88M and estimated current cash of -$1.7M.
The stock's trend appears to be bearish, with potential shorting opportunities and a risk of a price drop below $1.88.

Generated by AI

Topics

Of the messages about ALUR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	6.68%
Announcements	—	—	100%	56.32%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	36.99%

Announcements· Feb 23

The FDA has approved Allurion Technologies' gastric balloon system, featuring the swallowable Smart Capsule, for patients with a BMI of 30-40 kg/m², providing access to approximately 80 million Americans with obesity.
The Allurion Smart Capsule offers a safe and effective alternative to GLP-1 drugs and bariatric surgery, with published data showing average total body weight loss of 14-20% when paired with behavioral support.
The approval is expected to make the device a standard tool in the comprehensive treatment of obesity in the United States, with Allurion Technologies estimating 20 million Americans have discontinued GLP-1 drugs, a number expected to reach 40 million by 2027.

Technical Analysis· Feb 23

The 50% trade on Allurion Technologies Inc. ($ALUR) has seen a nice consolidation move, which could lead to a huge move at the end of the day or a breakdown.
Key levels to watch for $ALUR include $1.75, $1.95, and $2.15, with the potential for a move into $2.4-$2.5 if it breaks $2.1.
$ALUR has reclaimed its VWAP and needs to close over $1.71 to reach a target of $2.22, with further targets of $2.64 if it breaks through.

Generated by AI

Community

Of the messages about ALUR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	87.76%	29.32%
Newcomers	—	—	12.24%	70.68%

Regulars· Feb 24

The company received FDA approval for its gastric balloon system, and an analyst upgraded the stock to Buy with a $3 price target.
The stock made a decent rebound from 1.61 to 1.81 after hours, and some regulars are buying as it drops, with a target of 0.80.
The company's exercise of warrants for $3.0 million in gross proceeds is seen as a significant development, and some participants are anticipating a drop followed by a rebound.

Newcomers· Mar 2

Allurion Technologies (ALUR) is planning to appeal the NYSE delisting notice due to failing to meet the $50M equity/market cap standard.
The company's stock price has been significantly impacted, with a 32.6% drop, amid the plans to appeal the delisting proceedings.
The delisting notice is a result of Allurion failing to regain listing compliance, with the NYSE citing the company's market cap as the reason for the delisting.

Generated by AI

Also Discussed

Investors talking about ALUR also mention

#	Name	Attention
1	Nvni Group LimitedNVNI	0%0
2	Silexion Therapeutics Corp.SLXN	0.03%-0.01
3	Reborn Coffee, Inc.REBN	0%+0
4	JWSM - Jaws Mustang Acquisition Corporation	——
5	Interactive Strength Inc.TRNR	0%0
6	Aclarion, Inc.ACON	0%0
7	REalloys Inc.BLBX	0%0
8	BTC Digital Ltd.BTCT	0%0
9	CVII - Churchill Capital Corp VII	——
10	RFAC - RF Acquisition Corp.	——

Allurion Technologies Inc.

Healthcare
Medical Devices

Allurion Technologies Inc. is a healthcare-focused company dedicated to developing non-invasive medical devices and technology solutions aimed at promoting weight loss and healthy living. The cornerstone of Allurion's offerings is the Elipse Balloon, a swallowable, intragastric balloon designed to aid in weight loss without the need for surgery or endoscopic procedures. This innovative device gradually inflates within the stomach, providing a temporary sense of fullness to patients, which helps reduce food intake. Allurion operates primarily within the medical technology and wellness sectors, targeting a global market that includes hospitals, clinics, and wellness centers. With obesity being a significant health concern worldwide, Allurion's non-surgical solutions garner attention for their potential impact on improving patient outcomes while reducing healthcare costs associated with obesity-related conditions. The company continues to evolve its technological platforms, incorporating digital tools to monitor and support patients throughout their weight loss journey, cementing its position in the intersection of health, technology, and consumer healthcare markets.

Website

Location

11 Huron Drive

Natick, MA, 01760

United States

Social

What share of all stock conversation is about ALUR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 3

Allurion Technologies Inc. (ALUR) plans to appeal NYSE delisting notice and execute a plan to regain compliance.
The company expects to continue trading on the NYSE despite the delisting proceedings initiated due to listing standard breaches.
Allurion Technologies cites FDA approval in 2026 and remediation steps as reasons for its plan to regain NYSE compliance.

Generated by AI

Sentiment

Of the messages about ALUR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	93.73% +14.44
Bearish	—	—	0%	6.27% -14.44

Bullish· Feb 24

$ALUR has been upgraded to Buy from Neutral by Chardan Capital with a price target of $3, citing FDA approval for its gastric balloon system and increased options for management.
The company has obtained FDA approval for its gastric balloon system, featuring the Allurion Smart Capsule, which significantly increases options available to management to support execution of its business plan.
$ALUR is expected to reach $200 million in revenue within 2 years, with a possible buy opportunity at $1.5-$2 billion range if the company delivers significantly good results.

Bearish· Feb 23

Allurion Technologies Inc. (ALUR) is likely to dilute to a price below $1 due to an 80% dilution risk.
The company has a negative cash position, with only 0.7 months of cash remaining based on a quarterly cash burn of -$7.88M and estimated current cash of -$1.7M.
The stock's trend appears to be bearish, with potential shorting opportunities and a risk of a price drop below $1.88.

Generated by AI

Topics

Of the messages about ALUR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	6.68%
Announcements	—	—	100%	56.32%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	36.99%

Announcements· Feb 23

The FDA has approved Allurion Technologies' gastric balloon system, featuring the swallowable Smart Capsule, for patients with a BMI of 30-40 kg/m², providing access to approximately 80 million Americans with obesity.
The Allurion Smart Capsule offers a safe and effective alternative to GLP-1 drugs and bariatric surgery, with published data showing average total body weight loss of 14-20% when paired with behavioral support.
The approval is expected to make the device a standard tool in the comprehensive treatment of obesity in the United States, with Allurion Technologies estimating 20 million Americans have discontinued GLP-1 drugs, a number expected to reach 40 million by 2027.

Technical Analysis· Feb 23

The 50% trade on Allurion Technologies Inc. ($ALUR) has seen a nice consolidation move, which could lead to a huge move at the end of the day or a breakdown.
Key levels to watch for $ALUR include $1.75, $1.95, and $2.15, with the potential for a move into $2.4-$2.5 if it breaks $2.1.
$ALUR has reclaimed its VWAP and needs to close over $1.71 to reach a target of $2.22, with further targets of $2.64 if it breaks through.

Generated by AI

Community

Of the messages about ALUR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	87.76%	29.32%
Newcomers	—	—	12.24%	70.68%

Regulars· Feb 24

The company received FDA approval for its gastric balloon system, and an analyst upgraded the stock to Buy with a $3 price target.
The stock made a decent rebound from 1.61 to 1.81 after hours, and some regulars are buying as it drops, with a target of 0.80.
The company's exercise of warrants for $3.0 million in gross proceeds is seen as a significant development, and some participants are anticipating a drop followed by a rebound.

Newcomers· Mar 2

Allurion Technologies (ALUR) is planning to appeal the NYSE delisting notice due to failing to meet the $50M equity/market cap standard.
The company's stock price has been significantly impacted, with a 32.6% drop, amid the plans to appeal the delisting proceedings.
The delisting notice is a result of Allurion failing to regain listing compliance, with the NYSE citing the company's market cap as the reason for the delisting.

Generated by AI

Allurion Technologies

Social

Mar 3

Sentiment

Bullish· Feb 24

Bearish· Feb 23

Topics

Announcements· Feb 23

Technical Analysis· Feb 23

Community

Regulars· Feb 24

Newcomers· Mar 2

Also Discussed

Allurion Technologies Inc.

Company Information

Location

Social

Mar 3

Sentiment

Bullish· Feb 24

Bearish· Feb 23

Topics

Announcements· Feb 23

Technical Analysis· Feb 23

Community

Regulars· Feb 24

Newcomers· Mar 2

Also Discussed